# US 10,117,914 B2 · Sheep nematode vaccine

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,117,914 B2
- Document ID: US10117914B2
- Status: Granted
- Kind: B2
- Application number: 15/661,727
- Filed: 2017-07-27
- Published: 2018-01-11
- Granted: 2018-11-06
- Earliest claimed: 2012-02-07
- Assignees: Moredun Research Institute
- Applicants: Moredun Research Institute
- Inventors: Jacqueline Matthews; Alasdair Justice Nisbet; David Knox
- Web page: https://patentgrep.com/patent/US10117914B2

## CPC

- A61K 39/0003: {Invertebrate antigens}
- C07K 14/4354: {from nematodes}
- C07K 16/18: against material from animals or humans
- A61K 2039/552: {Veterinary vaccine}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention is based upon the identification of a number of antigens derived from species of the genus Teladorsagia, which can be used to raise immune responses in animals—particularly those animals susceptible or predisposed to infection by (or with) one or more Teladorsagia species. The antigens may be exploited to provide compositions and vaccines for raising protective immune responses in animals—the protective immune responses serving to reduce, prevent, treat or eliminate Teladorsagia infections/infestations.

## Claims

### Claim 1

A method of raising an immune response to Teladorsagia in an animal, said method comprising a step of administering to an animal, an immunogenic amount of Teladorsagia calcium-dependent apyrase-1 (Tci-APY-1) antigen.

### Claim 2 (depends on 1)

The method of claim 1, wherein the Tci-APY-1 antigen comprises a sequence that has at least 80%, 85%, 90% or 95% identity to the amino acid sequence of SEQ ID NO: 6.

### Claim 3 (depends on 1)

The method of claim 1, wherein the Tci-APY-1 antigen comprises a sequence that has at least 95% identity to the amino acid sequence of SEQ ID NO: 6.

### Claim 4 (depends on 1)

The method of claim 1, wherein the animal is an ovine animal, a bovine animal, a sheep or a goat.

### Claim 5 (depends on 1)

The method of claim 1, wherein the Tci-APY-1 antigen is a recombinant Tci-APY-1 antigen.

### Claim 6 (depends on 1)

The method of claim 1, wherein the immune response is a protective immune response.

### Claim 7 (depends on 1)

The method of claim 1, wherein the immune response reduces host T. circumcincta faecal egg counts (FECs) and luminal T. circumcincta burdens.

### Claim 8 (depends on 1)

The method of claim 1, wherein the Tci-APY-1 antigen is admixed with another vaccine, polypeptide, adjuvant, diluent or excipient.

### Claim 9 (depends on 1)

The method of claim 1, wherein the method further comprises a step of administering to an animal, an immunogenic amount of one or more T. circumcincta (Tci) antigens selected from the group consisting of:
(i) astacin-like metalloproteinase-1 (Tci-MEP-1);
(ii) cathepsin F-1 (Tci-CF-1);
(iii) excretory/secretory protein (unknown function: Tci-ES20);
(iv) transforming growth protein 2-like protein (a TGFβ homologue: Tci-TGH-2);
(v) activation associated secretory protein (Tci-ASP-1);
(vi) macrophage migration inhibitory factor (Tci-MIF-1);
(vii) surface associated antigen (Tci-SAA-1); and
(viii) an antigen encoded by a sequence exhibiting at least 95% identity with an amino acid sequence of degree of identity to a sequence of SEQ ID NOS:7, 1, 2, 3, 4, 5 or 8.

### Claim 10 (depends on 1)

The method of claim 1, wherein the method further comprises a step of administering to an animal an immunogenic amount of the T. circumcincta (Tci) antigen, astacin-like metalloproteinase-1 (Tci-MEP-1).